Tumor microenvironment-activated theranostic nanozymes for trimodal imaging-guided combined therapy

Hu, Pengcheng; Xu, Jie; Li, Qiushi; Sha, Jingyun; Zhou, Hong; Wang, Xuemeng; Xing, Yujuan; Wang, Yong; Gao, Kai; Xu, Kai; Zheng, Shaohui

doi:10.1016/j.jcis.2024.01.114

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a novel nanozyme, Au NBPs@Pt NCs-ICG, emerged as a promising candidate for multimodal imaging and an excellent therapeutic agent for breast cancer. 1 In a recent study, RVG-NV-NPs, a traceable neural nanocomplex, was designed for the imaging-guided delivery of bexarotene to brain for the treatment of Alzheimer's disease. 2 Furthermore, a polydopamine-coated 2D nanocomplex was recently developed as a high-affinity photothermal signal tag for lateral flow immunoassay-based dual-signal detection of Salmonella typhimurium.…”

Section: Introductionmentioning

confidence: 99%

“…The surface of the nanoparticles may be chemically altered to enable the attachment of various ligands, which can be used to transform them into vehicles for targeted delivery, diagnostic agents, fluorescent tags, biosensors, and other practical biological tools. Recently, a novel nanozyme, Au NBPs@Pt NCs-ICG, emerged as a promising candidate for multimodal imaging and an excellent therapeutic agent for breast cancer . In a recent study, RVG-NV-NPs, a traceable neural nanocomplex, was designed for the imaging-guided delivery of bexarotene to brain for the treatment of Alzheimer’s disease .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advancing Era and Rising Concerns in Nanotechnology-Based Cancer Treatment

Tiwari,

Gupta,

Verma

et al. 2024

ACS Chem. Health Saf.

View full text Add to dashboard Cite

Cancer is one of the most prevalent causes of mortality worldwide. The arena of cancer diagnosis and therapy has undergone a tremendous revolution since the development of nanotechnology. Due to their nanosize and biocompatibility, nanoparticles are extensively employed for gene therapy and targeted drug delivery. Nanotechnology-based approaches have also shown promising advancements in the utilization of extracellular vesicles for cancer diagnosis, prognosis, and therapy. Apart from this, the CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9)-based nanotherapy and the development of therapeutic nanovaccines have also demonstrated encouraging results in revolutionizing cancer treatment. Nanotechnology-based molecular imaging and contrast agents can detect cancer at very early stages, allowing for prompt treatment and better patient outcomes. Although nanoparticles offer multiple benefits for drug administration, they additionally possess certain pharmacokinetic limitations, such as body clearance, restricted tissue penetration, confrontation with biological barriers, biodistribution, and accumulation. However, improvements in nanoparticle design are intended to resolve safety issues and enhance the therapeutic effects of these particles in a variety of disease complications. While nanotechnology has demonstrated immense potential in the treatment and diagnosis of cancer, there are still several challenges to overcome, including guaranteeing the safety of nanomaterials, taking into account regulatory issues, and creating scalable and affordable solutions. Nevertheless, new developments in nanotechnology and current research hold promise for further revolutionizing cancer detection and treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%